Cancer drug maker Biostar shines on Hong Kong market debut
Unusually for a newly listed biotech, the company has already launched a commercial product – a flagship oncology drug that was developed using synthetic biotechnology Key Takeaways: The active agent…
Recent Articles
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- TransThera seeks Hong Kong IPO to sustain cancer drug research
